EAST LANSING, MI, Iaso Therapeutics recently closed the first tranche of the company's $1.25M Series Seed Preferred round of financing.
Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company's $1.25M Series Seed Preferred round of financing.
Participating in the round was the Michigan Rise Pre-Seed III Fund, Red Cedar Ventures Pre-Seed Fund and Michigan-based angel investors. Iaso Therapeutics is also eligible to receive up to $125K in funding from the Michigan Small Business Development Center and Michigan Economic Development Corporation's Emerging Technology Fund, leveraging a successful National Science Found Phase II SBIR grant in March 2022.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about